Market Place
Sourcing Support
Keros Therapeutics to Present at Guggenheim Healthcare Conference
06 Nov 2024 //
GLOBENEWSWIRE
Keros Therapeutics Reports Q3 2024 Financials & Highlights
06 Nov 2024 //
GLOBENEWSWIRE
Keros Therapeutics to Present at ASH 2024 Annual Meeting
05 Nov 2024 //
GLOBENEWSWIRE
Keros Appoints Yung H. Chyung, M.D., As Chief Medical Officer
16 Oct 2024 //
GLOBENEWSWIRE
Keros Therapeutics Updates Cantor Conference Presentation Time
12 Sep 2024 //
GLOBENEWSWIRE
Keros Therapeutics Announces Update on Enrollment in the Phase 2 TROPOS Trial
03 Sep 2024 //
GLOBENEWSWIRE
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
28 Aug 2024 //
GLOBENEWSWIRE
Keros Therapeutics Reports Second Quarter 2024 Financial Results
07 Aug 2024 //
GLOBENEWSWIRE
Keros Therapeutics Presents Elritercept Data At EHA 2024
17 Jun 2024 //
GLOBENEWSWIRE
Keros Therapeutics announces leadership updates
17 Jun 2024 //
GLOBENEWSWIRE
Keros Therapeutics to Host a Corporate Update Conference Call and Webcast
04 Jun 2024 //
GLOBENEWSWIRE
Keros To Present At Goldman Sachs Healthcare Conference
03 Jun 2024 //
GLOBENEWSWIRE
Keros Therapeutics Appoints Jean-Jacques Bienaim© to its Board of Directors
28 May 2024 //
GLOBENEWSWIRE
Keros Therapeutics To Present At EHA Congress 2024
14 May 2024 //
GLOBENEWSWIRE
Keros Q1 2024 Results, Recent Business Highlights
08 May 2024 //
GLOBENEWSWIRE
Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050
14 Mar 2024 //
GLOBENEWSWIRE
Keros to Present at Leerink Partners 2024 Global Biopharma Conference
05 Mar 2024 //
GLOBENEWSWIRE
Keros Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
28 Feb 2024 //
GLOBENEWSWIRE
Keros To Present at Pulmonary Vascular Research Institute 2024 Annual Congress
29 Jan 2024 //
PRESS RELEASE
Keros Therapeutics Announces Closing of Upsized Public Offering of Common Stock
09 Jan 2024 //
GLOBENEWSWIRE
Keros Therapeutics to Develop KER-065 for the Treatment of Obesity
03 Jan 2024 //
GLOBENEWSWIRE
Keros Therapeutics Announces Proposed Public Offering of Common Stock
03 Jan 2024 //
GLOBENEWSWIRE
Keros Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
03 Jan 2024 //
GLOBENEWSWIRE
Keros Therapeutics Presents Clinical Data from its KER-050 Program
11 Dec 2023 //
GLOBENEWSWIRE
Keros Therapeutics to Present at Upcoming Healthcare Conferences
07 Nov 2023 //
GLOBENEWSWIRE
Keros Therapeutics Reports Third Quarter 2023 Financial Results
06 Nov 2023 //
GLOBENEWSWIRE
Keros to Present at the 65th American Society of Hematology Annual Meeting
02 Nov 2023 //
GLOBENEWSWIRE
Keros Therapeutics Presents Preclinical Data from its KER-065 Program
04 Oct 2023 //
GLOBENEWSWIRE
Keros Therapeutics to Present at Upcoming Healthcare Conferences
05 Sep 2023 //
GLOBENEWSWIRE
Keros Reports Second Quarter 2023 Financial Results
07 Aug 2023 //
GLOBENEWSWIRE
Keros Therapeutics to Host Conference to Provide an Overview of TROPOS
27 Jul 2023 //
GLOBENEWSWIRE
Keros Therapeutics to Host Conference to Provide an Overview of TROPOS
24 Jul 2023 //
GLOBENEWSWIRE
Keros Announces Update to Participation at Goldman Sachs Healthcare Conference
12 Jun 2023 //
GLOBENEWSWIRE
Keros Therapeutics Presents Trial and Preclinical Study Results from its KER-050
09 Jun 2023 //
GLOBENEWSWIRE
Keros to Present at Goldman Sach 44th Annual Global Healthcare Conference
07 Jun 2023 //
GLOBENEWSWIRE
Keros Presents Preclinical and Clinical Data from its KER-012 Program
22 May 2023 //
GLOBENEWSWIRE
Keros to Present at 28th Annual Congress of the European Hematology Association
11 May 2023 //
GLOBENEWSWIRE
Keros Therapeutics Reports Recent Business Highlights and 1Q 2023 FYR
04 May 2023 //
GLOBENEWSWIRE
Keros Therapeutics Appoints Alpna Seth, Ph.D., to its Board of Directors
19 Apr 2023 //
GLOBENEWSWIRE
Keros Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
03 Mar 2023 //
GLOBENEWSWIRE
Keros Therapeutics to Present at Cowen’s 43rd Annual Health Care Conference
01 Mar 2023 //
GLOBENEWSWIRE
Keros Therapeutics Presents Clinical Data from its KER-050 and KER-047 Programs
12 Dec 2022 //
GLOBENEWSWIRE
Keros Therapeutics to Present at Upcoming Healthcare Conferences
22 Nov 2022 //
GLOBENEWSWIRE
Keros Therapeutics Presents Preclinical Data from its KER-012 Program
07 Nov 2022 //
GLOBENEWSWIRE
Keros Therapeutics Reports Third Quarter 2022 Financial Results
03 Nov 2022 //
GLOBENEWSWIRE
Keros to Present at the 64th American Society of Hematology Annual Meeting
03 Nov 2022 //
GLOBENEWSWIRE
Keros Therapeutics Presents Additional Clinical Data from its KER-012 Program
12 Sep 2022 //
GLOBENEWSWIRE
Keros Therapeutics to Present at the Morgan Stanley 20th Annual GHC
06 Sep 2022 //
GLOBENEWSWIRE
Keros to Present at the American Society for Bone and Mineral Research
06 Sep 2022 //
GLOBENEWSWIRE
Keros Therapeutics Reports Second Quarter 2022 Financial Results
04 Aug 2022 //
GLOBENEWSWIRE
Keros Therapeutics Presents Results from PC Study of RKER-012 in PAH
13 Jun 2022 //
GLOBENEWSWIRE
Keros Presents Results from KER-050 & PC Data from ALK2 Inhibitor Program
10 Jun 2022 //
GLOBENEWSWIRE
Keros Announces Prelim Results from its Ongoing PI Trial of KER-012
18 May 2022 //
GLOBENEWSWIRE
Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 in PAH
17 May 2022 //
GLOBENEWSWIRE
Keros Therapeutics to Present at the 27th Annual Congress of the EHA
12 May 2022 //
GLOBENEWSWIRE
Keros Therapeutics Reports First Quarter 2022 Financial Results
05 May 2022 //
GLOBENEWSWIRE
Keros Tx Reports Q4 and FY 2021 Financial Results
09 Mar 2022 //
GLOBENEWSWIRE
Keros Therapeutics to Present at the 11th Annual SVB Leerink Conference
11 Feb 2022 //
GLOBENEWSWIRE
Keros Therapeutics Appoints Christopher Rovaldi as Chief Operating Officer
31 Jan 2022 //
GLOBENEWSWIRE
Keros Presents Clinical Trial and Preclinical Study Results
13 Dec 2021 //
GLOBENEWSWIRE
